Merck Serono headquarters

Merck Serono signs neurodegenerative collaboration

pharmafile | June 9, 2011 | News story | Research and Development Affectis Pharmaceuticals, Merck Serono 

Merck Serono has struck a deal with biotech firm Affectis Pharmaceuticals to develop oral neurodegeneration compounds.

The companies will commercialise drugs that target P2X7 receptors, which are believed to be involved in the neuroinflammation process observed in some central nervous system diseases.

Merck Serono’s executive VP for Global Research and Development Dr Bernhard Kirschbaum said: “This partnership with Affectis reflects our long-term commitment to developing innovative treatments for neurodegenerative diseases, where unmet medical need still remains.”

Merck Serono will have exclusive rights to develop new compounds in return for making an upfront payment to Affectis of 2.4 million euros.

Advertisement

The German biotech could also be in line for 277 million euros in milestone payments related to the first three products expected to emerge from the collaboration, as well as undisclosed loyalties.

Affectis Pharmaceuticals’ chief executive Dr Manfred Ruediger said: “This agreement validates Affectis’ strategy to focus on small molecules that potentially target the neuroinflammatory aspect of some neurodegenerative diseases. We look forward to collaborating with Merck Serono, an industry leader in the field.”

The collaboration will also see the companies focus on P2X7 antagonist optimisation.

P2X7 is an ATP-gated ion channel receptor which is essential for the maturation and release of the pro-inflammatory cytokines. It is found on brain cells, which are activated by high levels of ATP in conditions of neuroinflammation.

Brett Wells

Related Content

sarah_opendi_and_rasha_kelej_at_the_campaigns_launch

Merck launches infertility programme in Uganda

Germany’s Merck has extended its infertility programme ‘Merck More than a Mother’ to Uganda, launching …

Merck rebrands as ‘science and technology’ company

Merck Group has rebranded to “reflect its transformation into a science and technology company”, and …

Merck KGaA reveals ASCO plans

Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, …

The Gateway to Local Adoption Series

Latest content